Αποτελέσματα αναζήτησης - "хроническая неспецифическая боль в спине"

1

Academic Journal

Efficacy and safety of the combined use of celecoxib, diacerein and a combination of glucosamine and chondroitin for the control of musculoskeletal pain associated with osteoarthritis and nonspecific back pain ; Эффективность и безопасность комбинированного применения целекоксиба, диацереина и комбинации глюкозамина и хондроитина для контроля скелетно-мышечной боли, связанной с остеоартритом и неспецифической болью в спине

Συγγραφείς: A. E. Karateev, E. Yu. Polishchuk, A. M. Lila, A. N. Ananyev, L. V. Ananyeva, A. V. Bondarev, A. A. Bondareva, A. R. Bukanbaeva, S. V. Vorster, S. A. Gadzhieva, D. G. Danilov, R. I. Eliseev, I. S. Zabelin, M. Yu. Ignatenko, I. V. Itkina, A. E. Kolesnikov, M. Yu. Konoplyanskaya, Yu. G. Krasnoyarova, S. I. Kukushkin, V. A. Lila, O. V. Makareva, V. S. Myagkikh, I. V. Nelgovskaya, N. V. Ocheredko, R. A. Panov, I. A. Polyakov, A. S. Prozorov, S. S. Rubina, M. E. Ryabochkina, M. A. Takhaev, E. R. Tokareva, T. V. Tolbina, M. I. Fominykh, V. V. Tsarev, E. I. Sharipova, M. V. Sheven, G. I. Shcherbakov, S. A. Yanchenkova, А. Е. Каратеев, Е. Ю. Полищук, А. М. Лила, А. Н. Ананьев, Л. В. Ананьева, А. В. Бондарев, А. А. Бондарева, А. Р. Буканбаева, С. В. Ворстер, С. А. Гаджиева, Д. Г. Данилов, Р. И. Елисеев, И. С. Забелин, М. Ю. Игнатенко, И. В. Иткина, А. Е. Колесников, М. Ю. Коноплянская, Ю. Г. Красноярова, С. И. Кукушкин, В. А. Лила, О. В. Макарьева, В. С. Мягких, И. В. Нельговская, Н. В. Очередько, Р. А. Панов, И. А. Поляков, А. С. Прозоров, С. С. Рубина, М. Э. Рябочкина, М. А. Тахаев, Е. Р. Токарева, Т. В. Толбина, М. И. Фоминых, В. В. Царев, Е. И. Шарипова, М. В. Шевень, Г. И. Щербаков, С. А. Янченкова

Συνεισφορές: The article is sponsored by РBF, Статья спонсируется ООО «ПАНБИО ФАРМ»

Πηγή: Modern Rheumatology Journal; Том 17, № 5 (2023); 97-106 ; Современная ревматология; Том 17, № 5 (2023); 97-106 ; 2310-158X ; 1996-7012

Θεματικοί όροι: комбинированная терапия, chronic nonspecific low back pain, celecoxib, diacerein, glucosamine, chondroitin, combination therapy, хроническая неспецифическая боль в спине, целекоксиб, диацереин, глюкозамин, хондроитин

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1484/1402; Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-265.; Veronese N, Cooper C, Bruyere O, et al. Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs. 2022 Sep;82(13):1347-1355. doi:10.1007/s40265-022-01773-5. Epub 2022 Sep 16.; Horecka A, Hordyjewska A, Blicharski T, Kurzepa J. Osteoarthritis of the knee – biochemical aspect of applied therapies: a review. Bosn J Basic Med Sci. 2022 Jul 29;22(4):488-498. doi:10.17305/bjbms.2021.6489.; Лила АМ, Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Современный алгоритм лечения остеоартрита. Терапия. 2022;(2):65-76.; Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3):337-350. doi:10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.; Li Z, Meng D, Li G, et al. Celecoxib Combined with Diacerein Effectively Alleviates Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways. Inflammation. 2015 Aug;38(4):1563-72. doi:10.1007/s10753-015-0131-3.; Pelletier JP, Raynauld JP, Dorais M, et al; DISSCO Trial Investigator Group. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology (Oxford). 2020 Dec 1;59(12):3858-3868. doi:10.1093/rheumatology/keaa072.; Huang H, Luo M, Liang H, et al. Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis. Pain Med. 2021 Feb 23;22(2):352-362. doi:10.1093/pm/pnaa230.; O'Donnell JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009 Nov-Dec;37(6):1789-802. doi:10.1177/147323000903700615.; Pavelka K, Bruyere O, Cooper C, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging.2016 Feb;33(2):75-85. doi:10.1007/s40266-016-0347-4. Erratum in: Drugs Aging. 2017 May;34(5):413.; Meng Z, Liu J, Zhou N. Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis. Arch Orthop Trauma Surg. 2023 Jan;143(1):409-421. doi:10.1007/s00402-021-04326-9.; Kongtharvonskul J, Woratanarat P, McEvoy M, et al. Efficacy of glucosamine plus diacerein versus monotherapy of glucosamine: a double-blind, parallel randomized clinical trial. Arthritis Res Ther. 2016 Oct 12;18(1):233. doi:10.1186/s13075-016-1124-9.; Lubis AMT, Siagian C, Wonggokusuma E, et al. Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial. Acta Med Indones. 2017 Apr;49(2):105-111.; Sterzi S, Giordani L, Morrone M, et al. The efficacy and safety of a combination of glucosamine hydrochloride, chondroitin sulfate and bio-curcumin with exercise in the treatment of knee osteoarthritis: a randomized, double-blind, placebo-controlled study. Eur J Phys Rehabil Med. 2016 Jun;52(3):321-30. Epub 2016 Mar 3.; Bottegoni C, Muzzarelli RA, Giovannini F, et al. Oral chondroprotection with nutraceuticals made of chondroitin sulphate plus glucosamine sulphate in osteoarthritis. Carbohydr Polym. 2014 Aug 30;109:126-38. doi:10.1016/j.carbpol.2014.03.033. Epub 2014 Mar 27.; Полищук ЕЮ, Каратеев АЕ, Потапова АС и др. Нужно оценить эффективность терапии? Спросите пациента! Научно-практическая ревматология. 2023; 61(3):361-368.; Migliore A, Gigliucci G, Alekseeva L, et al. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Ther Adv Musculoskelet Dis. 2019 Dec 19:11:1759720X19893800. URL: 10.1177/1759720X19893800. eCollection 2019.; Louati K, Berenbaum F. Fatigue in chronic inflammation – a link to pain pathways. Arthritis Res Ther. 2015 Oct 5;17:254. URL: https://www.researchgate.net/publication/283033721_Fatigue_in_chronic_inflammation_-_a_link_to_pain_pathways.; Enns MW, Bernstein CN, Kroeker K, et al; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. PLoS One. 2018 Jun 7;13(6):e0198975. doi:10.1371/journal.pone.0198975.; Aquilina J, Neves JB, Tran MG. An overview of study designs. Br J Hosp Med (Lond). 2020 May 2;81(5):1-6. doi:10.12968/hmed.2020.0127. Epub 2020 May 4.; Bosdriesz JR, Stel VS, van Diepen M, et al. Evidence-based medicine-When observational studies are better than randomized controlled trials. Nephrology (Carlton). 2020 Oct;25(10):737-743. doi:10.1111/nep.13742. Epub 2020 Jul 2.; Puljak L, Marin A, Vrdoljak D, et al. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017 May 22;5(5):CD009865. doi:10.1002/14651858.CD009865.pub2.; Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;(2):CD005117. doi:10.1002/14651858.CD005117.pub3.; Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013 Jan 8;15(1):R6. doi:10.1186/ar4134.; Cheng BR, Chen JQ, Zhang XW, et al. Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. PLoS One. 2021 Dec 21;16(12):e0261239. doi:10.1371/journal.pone.0261239.; Honvo G, Reginster JY, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019 Apr;36(Suppl 1):65-99. doi:10.1007/s40266-019-00662-z.; Каратеев АЕ, Алексеева ЛИ. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоАртрозе). Научно-практическая ревматология. 2015; 53(2):169-174.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1484
https://doi.org/10.14412/1996-7012-2023-5-97-106

View record from BASE

2

Academic Journal

Comorbidities and therapy for chronic non-specific low back pain and fibromyalgia ; Сопутствующие расстройства и терапия при хронической неспецифической боли в нижней части спины и фибромиалгии

Συγγραφείς: T. I. Nasonova, E. V. Parfenova, Т. И. Насонова, Е. В. Парфенова

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 3 (2022); 26-31 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 3 (2022); 26-31 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-3

Θεματικοί όροι: антиконвульсанты, chronic nonspecific back pain, kinesitherapy, cognitive behavioral therapy, antidepressants, anticonvulsants, хроническая неспецифическая боль в спине, кинезитерапия, когнитивно-поведенческая терапия, антидепрессанты

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1820/1410; Hagen M, Madhavan T, Bell J. Combined analysis of 3 cross-sectional surveys of pain in 14 countries in Europe, the Americas, Australia, and Asia: impact on physical and emotional aspects and quality of life. Scand J Pain. 2020 Jul 28;20(3):575-89. doi:10.1515/sjpain-2020-0003; Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi:10.1016/j.ejpain.2005.06.009. Epub 2005 Aug 10.; Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain. 2015 Jun;156(6):1003-7. doi:10.1097/j.pain.0000000000000160; Kim W, Jin YS, Lee CS, et al. Influence of knee pain and low back pain on the quality of life in adults older than 50 years of age. PM R. 2015 Sep;7(9):955-61. doi:10.1016/j.pmrj.2015.03.002. Epub 2015 Mar 7.; Kawai K, Kawai AT, Wollan P, Yawn BP. Adverse impacts of chronic pain on healthrelated quality of life, work productivity, depression and anxiety in a community-based study. Fam Pract. 2017 Nov 16;34(6):656-61. doi:10.1093/fampra/cmx034; Witt EA, Kenworthy J, Isherwood G, Dunlop WC. Examining the association between pain severity and quality-of-life, work-productivity loss, and healthcare resource use among European adults diagnosed with pain. J Med Econ. 2016 Sep;19(9):858-65. doi:10.1080/13696998.2016.1178127. Epub 2016 May 4.; Hurwitz EL, Randhawa K, Yu H, et al. The Global Spine Care Initiative: a summary of the global burden of low back and neck pain studies. Eur Spine J. 2018 Sep;27(Suppl 6):796-801. doi:10.1007/s00586-017-5432-9. Epub 2018 Feb 26.; Jones GT, Atzeni F, Beasley M, et al. The prevalence of fibromyalgia in the general population: A comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheum. 2015 Feb;67(2):568-75. doi:10.1002/art.38905; Häuser W, Kosseva M, Üceyler N, et al. Emotional, physical, and sexual abuse in fibromyalgia syndrome: A systematic review with meta-analysis. Arthritis Care Res (Hoboken). 2011 Jun;63(6):808-20. doi:10.1002/acr.20328; Wolfe F, Ross K, Anderson J, Russell IJ. Aspects of fibromyalgia in the general population: Sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995 Jan;22(1):151-6.; Давыдов ОС, Глебов МВ. Фибромиалгия. Российский журнал боли. 2020;18(3):66-74. doi:10.17116/pain20201803166; Суслова ЕЮ, Парфенов ВА. Комплексный подход к лечению пациентов с хронической люмбалгией. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2015;115(10-2):16-21. doi:10.17116/jnevro201511510216-21; Ламкова ИА, Парфенов ВА. Инсомния при хронической неспецифической люмбалгии. Неврология, нейропсихиатрия, психосоматика. 2021;13(5):62-7. doi:10.14412/2074-2711-2021-5-62-67; Ciaramella A, Poli P. Chronic Low Back Pain: Perception and Coping With Pain in the Presence of Psychiatric Comorbidity. J Nerv Ment Dis. 2015;203(8):632-40. doi:10.1097/NMD.0000000000000340; Nijs J, Mairesse O, Neu D, et al. Sleep Disturbances in Chronic Pain: Neurobiology, Assessment, and Treatment in Physical Therapist Practice. Phys Ther. 2018;98(5):325-35. doi:10.1093/ptj/pzy020; Bilge U, Sari YE, Balcioglu H, et al. Prevalence of comorbid diseases in patients with fibromyalgia: A retrospective cross-sectional study. J Pak Med Assoc. 2018 May;68(5):729-32.; Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry. 2006;67(8):1219-25. doi:10.4088/jcp.v67n0807; Bradley LA. Psychiatric comorbidity in fibromyalgia. Curr Pain Headache Rep. 2005 Apr;9(2):79-86. doi:10.1007/s11916-005-0042-3; Airaksinen O, Brox JI, Cedraschi C, et al; COST B13 Working Group on Guidelines for Chronic Low Back Pain. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006 Mar;15 Suppl 2(Suppl 2):S192-300. doi:10.1007/s00586-006-1072-1; Bernardy K, Klose P, Busch AJ, et al. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013 Sep 10;2013(9):CD009796. doi:10.1002/14651858.CD009796.pub2; Carville SF, Arendt-Nielsen L, Bliddal H, et al; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008 Apr;67(4):536-41. doi:10.1136/ard.2007.071522; Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blindtrial. J Pain. 2010 Dec;11(12):1282-90. doi:10.1016/j.jpain.2010.03.002. Epub 2010 May 15.; Migliorini F, Maffulli N, Eschweiler J, et al. The pharmacological management of chronic lower back pain. Expert Opin Pharmacother. 2021 Jan;22(1):109-19. doi:10.1080/14656566.2020.1817384. Epub 2020 Sep 4.; Макаров СА, Чурюканов МВ, Чурюканов ВВ. Антидепрессанты в лечении боли. Российский журнал боли. 2016;3-4(51):74-84.; Urquhart DM, Hoving JL, Assendelft WW, Roland M, van Tulder MW. Antidepressants for non-specific low back pain. Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD001703. doi:10.1002/14651858.CD001703.pub3; Российское межрегиональное общество по изучению боли. Клинические рекомендации Диагностика и лечение скелетно-мышечных (неспецифических) болей в нижней части спины. 2021. 47 с. Режим доступа: https://painrussia.ru/publications/referencematerials-and-guides/%D0%91%D0%A1_%D0%A0%D0%9E%D0%98%D0%91_2020.pdf; Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017 Feb;76(2):318-28. doi:10.1136/annrheumdis-2016-209724. Epub 2016 Jul 4.; Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal antiinflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. doi:10.1002/14651858.CD000396.pub3; Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016 Dec;46(3):319-29. doi:10.1016/j.semarthrit.2016.08.012; Arnold LM, Bennett RM, Crofford LJ, et al. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019;20(6):611-28. doi:10.1016/j.jpain.2018.10.008; Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990 Feb;33(2):160-72. doi:10.1002/art.1780330203; Теплякова ОВ, Попов АА, Волкова ЛИ, Сарапулова АВ. Фибромиалгия: клиническая картина и варианты заболевания. Современная ревматология. 2020;14(2):45-51. doi:10.14412/1996-7012-2020-2-45-51; Стороженко ОН. Распространенность и факторы риска синдромов фибромиалгии и хронической генерализованной боли в популяции г. Екатеринбурга: Дис. … канд. мед. наук. Москва; 2004. 171 c. Доступно по ссылке: https://rusneb.ru/catalog/000199_000009_004060836/; Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep. 2011 Dec;13(6):513-20. doi:10.1007/s11926-011-0206-6; De Oliveira Paes Leme M, Yuan SLK, Oliveira Magalhaes M, et al. Pain and quality of life in knee osteoarthritis, chronic low back pain and fibromyalgia: a comparative cross-sectional study. Reumatismo. 2019 Jul 9;71(2):68-74. doi:10.4081/reumatismo.2019.1104; Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis. 2005 Mar;64(3):396-402. doi:10.1136/ard.2003.019711; O’Connor SR, Tully MA, Ryan B, et al. Walking exercise for chronic musculoskeletal pain: systematic review and meta-analysis. Arch Phys Med Rehabil. 2015 Apr;96(4):724-734.e3. doi:10.1016/j.apmr.2014.12.003. Epub 2014 Dec 19.; Pergolizzi JV Jr, Raffa RB, Taylor R Jr, et al. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract. 2013 Mar;13(3):239-52. doi:10.1111/j.1533-2500.2012.00578.x; Fitzcharles MA, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz. 2016 Feb;30(1):47-61. doi:10.1007/s00482-015-0084-3; Angst F, Brioschi R, Main CJ, et al. Interdisciplinary rehabilitation in fibromyalgia and chronic back pain: a prospective outcome study. J Pain. 2006 Nov;7(11):807-15. doi:10.1016/j.jpain.2006.03.009; Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag. May-Jun 2013;18(3):119-26. doi:10.1155/2013/918216; Beck JS. Cognitive behavior therapy: basics and beyond. 2nd ed. New York: The Guilford Press; 2011. 394 p.; Sosa-Reina MD, Nunez-Nagy S, Gallego-Izquierdo T, et al. Effectiveness of Therapeutic Exercise in Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. BioMed Res Int. 2017;2017:1-14. doi:10.1155/2017/2356346; Rico-Villademoros F, Slim M, Calandre EP. Amitriptyline for the treatment of fibromyalgia: a comprehensive review. Exp Rev Neurother. 2015;15(10):1123-50. doi:10.1586/14737175.2015.1091726; Häuser W, Urrutia G, Tort S, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD010292. doi:10.1002/14651858.cd0102; Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013 Nov 11;2013(11):CD010567. doi:10.1002/14651858.cd010567; Moore A, Wiffen P, Kalso E. Antiepileptic drugs for neuropathic pain and fibromyalgia. JAMA. 2014;312(2):182. doi:10.1001/jama.2014.6336

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1820
https://doi.org/10.14412/2074-2711-2022-3-26-31

View record from BASE

3

Academic Journal

Results of an open multicenter non-interventional study of clinical efficacy and tolerability of etoricoxib in osteoarthritis and nonspecific back pain with additional evaluation of the effect of the drug on the «central» manifestations of pain ; Результаты открытого многоцентрового неинтервенционного исследования клинической эффективности и переносимости эторикоксиба при остеоартрите и неспецифической боли в спине с дополнительной оценкой влияния препарата на «центральные» проявления боли

Συγγραφείς: A. E. Karateev, E. Yu. Polishchuk, E. S. Filatova, V. N. Amirdzhanova, V. A. Nesterenko, A. S. Potapova, S. I. Glukhova, A. M. Lila, A. V. Sarapulova, A. A. Mukhin, O. S. Lyusina, L. A. Levasheva, E. V. Kryukova, D. K. Klein, N. V. Kichai, M. A. Kabalyk, N. E. Dobrokhotova, Yu. Yu. Grabovetskaya, L. A. Blagodareva, E. V. Zonova, S. M. Zwinger, P. P. Popov, А. Е. Каратеев, Е. Ю. Полищук, Е. С. Филатова, В. Н. Амирджанова, В. А. Нестеренко, А. С. Потапова, С. И. Глухова, А. М. Лила, А. В. Сарапулова, А. А. Мухин, О. С. Люсина, Л. А. Левашева, Е. В. Крюкова, Д. К. Клейн, Н. В. Кичай, М. А. Кабалык, Н. Э. Доброхотова, Ю. Ю. Грабовецкая, Л. А. Благодарева, Е. В. Зонова, С. М. Цвингер, П. П. Попов

Πηγή: Modern Rheumatology Journal; Том 16, № 2 (2022); 34-42 ; Современная ревматология; Том 16, № 2 (2022); 34-42 ; 2310-158X ; 1996-7012

Θεματικοί όροι: эторикоксиб, chronic nonspecific back pain, central sensitization, CSI, etoricoxib, хроническая неспецифическая боль в спине, центральная сенситизация

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1272/1226; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020. 448 с.; Clauw DJ, Essex MN, Pitman V, Jones KD. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. Postgrad Med. 2019 Apr;131(3):185-98. doi:10.1080/00325481.2019.1574403. Epub 2019 Feb 11.; Trouvin AP, Perrot S. Pain in osteoarthritis. Implications for optimal management. Joint Bone Spine. 2018 Jul;85(4):429-34. doi:10.1016/j.jbspin.2017.08.002.; Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018 Jun 9; 391(10137):2356-67. doi:10.1016/S0140-6736(18)30480-X. Epub 2018 Mar 21.; Mathias K, Amarnani A, Pal N, et al. Chronic Pain in Patients with Rheumatoid Arthritis. Curr Pain Headache Rep. 2021 Jul 16;25(9):59. doi:10.1007/s11916-021-00973-0.; Curatolo M, Arendt-Nielsen L. Central hypersensitivity in chronic musculoskeletal pain. Phys Med Rehabil Clin N Am. 2015 May;26(2):175-84. doi:10.1016/j.pmr.2014.12.002.; Arant KR, Katz JN, Neogi T. Quantitative sensory testing: identifying pain characteristics in patients with osteoarthritis. Osteoarthritis Cartilage. 2022 Jan;30(1):17-31. doi:10.1016/j.joca.2021.09.011.; Magni A, Agostoni P, Bonezzi C, et al. Management of Osteoarthritis: Expert Opinion on NSAIDs. Pain Ther. 2021 Dec; 10(2):783-808. doi:10.1007/s40122-021-00260-1.; Takemoto JK, Reynolds JK, Remsberg CM, et al. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20. doi:10.2165/00003088-200847110-00002.; Renner B, Zacher J, Buvanendran A, et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Naunyn Schmiedebergs Arch Pharmacol. 2010 Feb;381(2):127-36. doi:10.1007/s00210-009-0482-0. Epub 2010 Jan 6.; Piirainen A, Kokki M, Hautajдrvi H, et al. The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. Clin Drug Investig. 2016 Jul;36(7):545-55. doi:10.1007/s40261-016-0400-4.; Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi:10.1097/j.pain.0000000000000562.; Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Nov;25(11):1781-91. doi:10.1016/j.joca.2017.07.009. Epub 2017 Aug 2.; https://painrussia.ru/publications/the-questionnaires-and-scales-to-assesspain/csi.default.ivp.php; Gervais-Hupe J, Pollice J, Sadi J, Carlesso LC. Validity of the central sensitization inventory with measures of sensitization in people with knee osteoarthritis. Clin Rheumatol. 2018 Nov;37(11):3125-32. doi:10.1007/s10067-018-4279-8. Epub 2018 Sep 3.; Есин ОР, Горобец ЕА, Хайруллин ИХ и др. Опросник центральной сенситизации — русскоязычная версия. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(6):51-6.; Бахтадзе МА, Чурюканов МВ, Кукушкин МЛ и др. Опросник для оценки центральной сенситизации: лингвистическая адаптация русскоязычной версии. Российский журнал боли. 2020;18(4):40-5.; Sheldon EA, Bird SR, Smugar SS, Tershakovec AM. Correlation of measures of pain, function, and overall response: results pooled from two identical studies of etoricoxib in chronic low back pain. Spine (Phila Pa 1976). 2008 Mar 1;33(5):533-8. doi:10.1097/BRS.0b013e3181657d24.; Da Costa BR, Pereira TV, Saadat P, et al. Effectiveness and safety of non-steroidal antiinflammatory drugs and opioid treatment for knee and hip osteoarthritis: network metaanalysis. BMJ. 2021 Oct 12;375:n2321. doi:10.1136/bmj.n2321.; Moore AR, Smugar SS, Wang H, et al. Numbers-needed-to-treat analyses – do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebocontrolled chronic low back pain trials. Pain. 2010 Dec;151(3):592-7. doi:10.1016/j.pain.2010.07.013.; Zolio L, Lim KY, McKenzie JE, et al. Systematic review and meta-analysis of the prevalence of neuropathic-like pain and/or pain sensitization in people with knee and hip osteoarthritis. Osteoarthritis Cartilage. 2021 Aug;29(8):1096-116. doi:10.1016/j.joca.2021.03.021. Epub 2021 May 8.; Schuttert I, Timmerman H, Petersen KK, et al. The Definition, Assessment, and Prevalence of (Human Assumed) Central Sensitisation in Patients with Chronic Low Back Pain: A Systematic Review. J Clin Med. 2021 Dec 17;10(24):5931. doi:10.3390/jcm10245931.; Каратеев АЕ. Эторикоксиб может использоваться при хронической неспецифической боли в спине: новое показание для хорошо известного препарата. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):125-30.; Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi:10.1371/journal.pone.0190798. eCollection 2018.; Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 Oct 4;296(13):1619-32. doi:10.1001/jama.296.13.jrv60015. Epub 2006 Sep 12.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1272
https://doi.org/10.14412/1996-7012-2022-2-34-42

View record from BASE

4

Academic Journal

Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug ; Эторикоксиб может использоваться при хронической неспецифической боли в спине: новое показание для хорошо известного препарата

Συγγραφείς: A. E. Karateev, А. Е. Каратеев

Συνεισφορές: This article has been supported by MSD., Статья спонсируется компанией «МСД Фармасьютикалс».

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 2 (2020); 125-130 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 2 (2020); 125-130 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-2

Θεματικοί όροι: безопасность, chronic nonspecific back pain, nonsteroidal anti-inflammatory drugs, etoricoxib, efficacy, safety, хроническая неспецифическая боль в спине, нестероидные противовоспалительные препараты, эторикоксиб, эффективность

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1317/1041; Парфенов ВА, Яхно НН, Кукушкин МЛ и др. Острая неспецифическая (скелетномышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2018;10(2):4–11. doi:10.14412/2074-2711-2018-2-4-11; Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7): 514-530. doi:10.7326/M16-2367. Epub 2017 Feb 14.; Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018 Nov; 27(11):2791-2803. doi:10.1007/s00586-018-5673-2. Epub 2018 Jul 3.; Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and sciatica: summary of NICE guidance. BMJ. 2017 Jan 6;356:i6748. doi:10.1136/bmj.i6748.; Allegri M, Montella S, Salici F, et al. Mechanisms of low back pain: a guide for diagnosis and therapy. Version 2. F1000Res. 2016 Jun 28 [revised 2016 Oct 11];5. pii: F1000 Faculty Rev-1530. eCollection 2016.; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159): 1789-1858. doi:10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.; Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11): 1688-1694. doi:10.1002/acr.22890.; Deyo R, Mirza S, Turner J, Martin B. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009 Jan-Feb;22(1): 62-8. doi:10.3122/jabfm.2009.01.080102.; Langenmaier AM, Amelung VE, Karst M, et al. Subgroups in chronic low back pain patients – a step toward cluster-based, tailored treatment in inpatient standard care: On the need for precise targeting of treatment for chronic low back pain. Ger Med Sci. 2019 Sep 11;17:Doc09. doi:10.3205/000275. eCollection 2019.; Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018 Feb;22(2):216-241.; Vardeh D, Mannion RJ, Woolf CJ. Toward a Mechanism-Based Approach to Pain Diagnosis. J Pain. 2016 Sep;17(9 Suppl):T50-69. doi:10.1016/j.jpain.2016.03.001.; Chou R, Deyo R, Friedly J, et al. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017 Apr 4;166(7):480-492. doi:10.7326/M16-2458. Epub 2017 Feb 14.; Ramos-Remus CR, Hunsche E, Mavros P, et al. Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico. Curr Med Res Opin. 2004 May;20(5):691-8.; Sheldon EA, Bird SR, Smugar SS, Tershakovec AM. Correlation of measures of pain, function, and overall response: results pooled from two identical studies of etoricoxib in chronic low back pain. Spine (Phila Pa 1976). 2008 Mar 1;33(5):533-8. doi:10.1097/BRS.0b013e3181657d24.; Peloso PM, Moore RA, Chen WJ, et al. Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial. Scand J Pain. 2016 Oct;13: 175-181. doi:10.1016/j.sjpain.2016.07.002. Epub 2016 Aug 10.; Kuritzky L, Samraj GP. Nonsteroidal antiinflammatory drugs in the treatment of low back pain. J Pain Res. 2012;5:579-90. doi:10.2147/JPR.S6775. Epub 2012 Nov 28.; O'Donnell JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009 Nov-Dec; 37(6):1789-802.; Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018 Mar 6;319(9): 872-882. doi:10.1001/jama.2018.0899.; Ahmedani BK, Peterson EL, Wells KE, et al. Long-term Management of Low Back Pain with Opioids and Non-steroidal Anti-inflammatory Drugs in a Health System. Am J Prev Med. 2016 Jun;50(6):e191-e193. doi:10.1016/j.amepre.2016.02.001. Epub 2016 Mar 9.; Enthoven WT, Roelofs PD, Deyo RA, et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016 Feb 10;2:CD012087. doi:10.1002/14651858; Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ, и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(1S):1-29. doi:10.14412/1995-4484-2018-1-29; Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005 May;39(5):854-62. Epub 2005 Apr 12.; Takemoto JK, Reynolds JK, Remsberg CM, et al. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20.; Kwiatkowska B, Majdan M, MastalerzMigas A, et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017;55(6):290-297. doi:10.5114/reum.2017.72626. Epub 2017 Dec 30.; Давыдов ОС. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования ЦОГ 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика. 2016;8(2):10–6. doi:10.14412/2074-2711-2016-2-10-16; Piirainen A, Kokki M, Hautajä rvi H, et al. The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. Clin Drug Investig. 2016 Jul; 36(7):545-55. doi:10.1007/s40261-016-0400-4.; Bickham K, Kivitz AJ, Mehta A, et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi:10.1186/s12891-016-1170-0.; Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal antiinflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6):1152-60. doi:10.1136/annrheumdis-2015-207677. Epub 2015 Aug 6.; Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov; 28(6):1021-1028. doi:10.1080/14397595.2018.1439694. Epub 2018 Mar 1.; Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.; Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi:10.1097/j.pain.0000000000000562.; Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Aug 2. pii: S1063-4584(17)31091-9.; Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain. 2003 Aug;4(6):307-15.; Pallay RM, Seger W, Adler JL, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257-66.; Moore RA, Smugar SS, Wang H, et al. Numbers-needed-to-treat analyses – do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain. 2010 Dec;151(3): 592-7. doi:10.1016/j.pain.2010.07.013.; Zerbini C, Ozturk ZE, Grifka J, et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, doubleblind study. Curr Med Res Opin. 2005 Dec; 21(12):2037-49.; Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005 May;21(5):715-22.; Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi:10.1371/journal.pone.0190798. eCollection 2018.; Каратеев АЕ, Погожева ЕЮ, Филатова ЕС, Амирджанова ВН. Эндоскопическая картина верхних отделов желудочно-кишечного тракта на фоне приема различных нестероидных противовоспалительных препаратов. Клиническая фармакология и терапия. 2018;27(4):40-5.; Curtis S, Ko A, Bolognese J, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006 Dec;22(12): 2365-74.; Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549):1771-81.; Каратеев АЕ. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018;12(2):64-72. doi:10.14412/1996-7012-2018-2-64-72; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79.; Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Expert Rev Clin Pharmacol. 2016 Sep 8:1-14.; Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal antiinflammatory drugs in controlled clinical trials. Clin Ther. 2004 Jan;26(1):70-83.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1317
https://doi.org/10.14412/2074-2711-2020-2-125-130

View record from BASE

5

Academic Journal